Background: Androgenic alopecia (AGA), commonly referred to as male pattern baldness, represents a prevalent condition characterized by hair loss in men worldwide. While genetic factors primarily influence AGA, hormonal imbalances, particularly involving androgens, play a significant role in its pathogenesis. Platelet-Rich Plasma (PRP) therapy has emerged as a promising treatment option for AGA in males, offering hope for effective solutions for hair loss. Objective: To evaluate the effectiveness of PRP injections in the treatment of androgenic alopecia in males. Methodology: In this prospective study spanning January 2023 to January 2024, 30 male patients with androgenic alopecia (AGA) were enrolled. Diagnosis relied on clinical evaluation, with AGA staging based on the Norwood-Hamilton scale. Patients underwent baseline blood workup and received four PRP injection sessions every three weeks. Visual assessments, digital photography, and a hair pull test were conducted at specified intervals. PRP was prepared from peripheral blood using centrifugation and activated with calcium chloride before injection into affected scalp areas using the nappage technique. Data analysis employed SPSS software, with continuous variables expressed as mean ± SD and categorical variables as numbers and percentages. Fisher’s exact test was used for qualitative data analysis, with significance set at p < 0.05. The study aimed to evaluate the effectiveness of PRP injections in treating AGA in males. Results: The study population's age distribution showcases a varied demographic, with the majority falling within the 28 to 47-year-old range, particularly dominant in the 38-47 years group (50%), followed by 28-37 years (36.67%), while individuals aged 18-27 years represent 13.33% of the total participants. In terms of male pattern baldness, the Modified Norwood Hamilton classification reveals a predominant presence of moderate to slightly advanced stages, with Grade III being the most prevalent (23.30%), followed by IIIa (16.67%) and IIa (16.67%). Additionally, Grade II accounts for 10% of the population, while the more severe stages, IV and IVa, collectively make up 18.50%. At baseline assessment, the majority of patients exhibited moderate hair loss (75%), with mild hair fall noted in 20% and severe hair fall in 5% of the cohort. Over the course of the study, visual assessment on a 7-point scale demonstrated a progressive improvement, with initially all participants showing no change, which decreased to 26% by the 4th month, accompanied by increasing percentages of mild (40.6% at 4th month), moderate (29.6% at 4th month), and excellent (3.7% at 4th month) improvements. Analysis of improvement in the fronto-temporal region compared to the vertex region indicated differences in distribution but lacked statistical significance across categories of improvement (p-values ranging from 0.15 to 1.00), with moderate improvement being more prevalent in the vertex region (50%) compared to the fronto-temporal region (23.8%). Conclusion: PRP therapy offers a straightforward and cost-effective approach to treating AGA in males. With high patient satisfaction rates and minimal adverse effects, PRP presents itself as a viable option for individuals who have not responded satisfactorily to conventional treatments.